Verification by RT-PCR and immunohistochemistry confirmed upregulation of CD9 and retinoic acid responder 1 gene (RARRES1) in regressive tumors, while MITF was upregulated in progressive melanomas [208]. This evidence concerns the gene MITF and melanoma.